Functional graphene oxide as cancer-targeted drug delivery system to selectively induce oesophageal cancer cell apoptosis
Source abstract
Abstract
Graphene oxides (GO) is a promising building material to fabricate desired drug delivery system due to its excellent physicochemical properties. In this study, an innovative nano-drug (Ori@GE11-GO) was constructed based on GE11 peptide functionalized GO for targeted delivery of oridonin to realize the specific recognition of tumour cells and enhance anticancer efficiency. GE11 surface modification onto GO significantly increased the cellular uptake of GO in EGFR overexpressed oesophageal cancer cells (KYSE-30 and EC109 cells) than that of normal cells, indicating the EGFR targeting effects of Ori@GE11-GO. The internalized Ori@GE11-GO could accumulate into lysosomes and significantly inhibit the viability of cancer cells. Moreover, Ori@GE11-GO could effectively induce KYSE-30 and EC109 cells cycle arrest, apoptosis, mitochondrial membrane potential (△Ψm) disruption through the activation of apoptotic signalling pathways and the inhibition of EGFR/Ras/Raf/MEK/ERK signalling pathway, showing potential use of Ori@GE11-GO for cancer treatment. Taken together, this study demonstrates a good strategy for the construction of bio-functionalized GO drug delivery nanosystem to improve the cancer targeting efficiency of anticancer medicines.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Graphene and Nanomaterials Applications · Nanoparticle-Based Drug Delivery · Nanoparticles: synthesis and applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
State Key Laboratory of Quality Research in Chinese Medicines, Macau University of Science and Technology
Department of Microbiology, Zhongshan School of Medicine, Key Laboratory for Tropical Diseases Control of the Ministry of Education, Sun Yat-sen University
Department of Microbiology and Immunology, University of Illinois at Chicago
Department of Chemistry, Jinan University
Funding
Macau Science and Technology Development Fund · China Postdoctoral Science Foundation
References (40)
Show source-provided references
1. 10.1016/j.rser.2015.12.12010.1016/j.rser.2015.12.120 ↗
2. 10.1016/j.msec.2018.01.00410.1016/j.msec.2018.01.004 ↗
3. 10.1517/17425247.2015.97876010.1517/17425247.2015.978760 ↗
4. 10.1080/21691401.2018.145026510.1080/21691401.2018.1450265 ↗
5. 10.1021/am402128s10.1021/am402128s ↗
6. 10.2147/IJN.S10540110.2147/IJN.S105401 ↗
7. 10.1016/j.biomaterials.2014.02.03210.1016/j.biomaterials.2014.02.032 ↗
8. 10.1016/j.ijbiomac.2018.02.15310.1016/j.ijbiomac.2018.02.153 ↗
9. Liu CC, Zhao JJ, Zhang R, et al. Multifunctionalization of graphene and graphene oxide for controlled release and targeted delivery of anticancer drugs. Am J Transl Res. 2017;9:5197–5219.
10. 10.1016/j.phrs.2016.11.03610.1016/j.phrs.2016.11.036 ↗
11. 10.18632/oncotarget.803310.18632/oncotarget.8033 ↗
12. 10.1016/j.ejphar.2018.02.04410.1016/j.ejphar.2018.02.044 ↗
13. 10.1038/s41419-017-0031-610.1038/s41419-017-0031-6 ↗
14. 10.1080/1061186X.2016.120058810.1080/1061186X.2016.1200588 ↗
15. 10.2147/IJN.S2758110.2147/IJN.S27581 ↗
16. 10.1080/10717544.2017.138672910.1080/10717544.2017.1386729 ↗
17. 10.1021/acs.molpharmaceut.6b0011610.1021/acs.molpharmaceut.6b00116 ↗
18. 10.1016/j.biomaterials.2013.06.00710.1016/j.biomaterials.2013.06.007 ↗
19. 10.1016/j.biomaterials.2016.05.04110.1016/j.biomaterials.2016.05.041 ↗
20. 10.3390/jpm801000410.3390/jpm8010004 ↗
21. 10.3390/pharmaceutics1001000210.3390/pharmaceutics10010002 ↗
22. 10.1016/j.biomaterials.2015.05.03610.1016/j.biomaterials.2015.05.036 ↗
23. 10.1021/ja803688x10.1021/ja803688x ↗
24. 10.1002/asia.20150127710.1002/asia.201501277 ↗
25. 10.3390/nano711038810.3390/nano7110388 ↗
26. 10.1186/s13046-017-0572-710.1186/s13046-017-0572-7 ↗
27. 10.18632/oncotarget.1579910.18632/oncotarget.15799 ↗
28. 10.2147/IJN.S11346910.2147/IJN.S113469 ↗
29. 10.1021/acsami.7b0687910.1021/acsami.7b06879 ↗
30. 10.1007/s11095-016-2007-010.1007/s11095-016-2007-0 ↗
31. 10.1016/j.jcis.2016.11.09710.1016/j.jcis.2016.11.097 ↗
32. 10.1016/j.neo.2018.02.00510.1016/j.neo.2018.02.005 ↗
33. 10.1016/j.ejphar.2018.03.02910.1016/j.ejphar.2018.03.029 ↗
34. 10.1016/j.bbamcr.2014.04.01710.1016/j.bbamcr.2014.04.017 ↗
35. 10.1016/j.biomaterials.2009.07.00810.1016/j.biomaterials.2009.07.008 ↗
36. 10.1016/j.phymed.2014.08.00210.1016/j.phymed.2014.08.002 ↗
37. 10.1038/nrc195310.1038/nrc1953 ↗
38. 10.1101/cshperspect.a01125410.1101/cshperspect.a011254 ↗
39. 10.3390/cancers905005210.3390/cancers9050052 ↗
40. 10.1002/ijc.3139810.1002/ijc.31398 ↗